

Chapter 80

REFERENCES

1. Weil MH, Shubin H. Proposed reclassification of shock states with special reference to distributive defects. In: Hinshaw L, Cox B, eds. *The Fundamental Mechanisms of Shock*. New York, NY: Plenum Press; 1972:13-23.
2. Rivers E, Nguyen B, Havstad S, et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. *N Engl J Med*. 2001;345(19):1368-1377.
3. Weil MH, Shubin H. The “VIP” approach to the bedside management of shock. *JAMA*. 1969;207:337-340.
4. Hollenberg SM, Ahrens TS, Annane D, et al. Practice parameters for hemodynamic support of sepsis in adult patients: 2004 update. *Crit Care Med*. 2004;32(9):1928-1948.
5. Vincent JL. Strategies in body fluid replacement. *Minerva Anesthesiol*. 2000;66(5):278-284.
6. Wilkes NJ, Woolf R, Mutch M, et al. The effects of balanced versus saline-based hetastarch and crystalloid solutions on acid-base and electrolyte status and gastric mucosal perfusion in elderly surgical patients. *Anesth Analg*. 2001;93(4):811-816.
7. Hunt TK. Surgical wound infections: an overview. *Am J Med*. 1981;70(3):712-718.
8. Lang K, Boldt J, Suttner S, Haisch G. Colloids versus crystalloids and tissue oxygen tension in patients undergoing major abdominal surgery. *Anesth Analg*. 2001;93(2):405-409.
9. Cochrane Injuries Group. Human albumin administration in critically ill patients: systematic review of randomized controlled trials. *BMJ*. 1998;317:235-240.
10. Finfer S, Bellomo R, Boyce N, et al. A comparison of albumin and saline for fluid resuscitation in the intensive care unit. *N Engl J Med*. 2004;350(22):2247-2256.
11. Vincent JL, Dubois MJ, Navickis RJ, Wilkes MM. Hypoalbuminemia in acute illness: is there a rationale for intervention? A meta-analysis of cohort studies and controlled trials. *Ann Surg*. 2003;237(3):319-334.
12. Vincent JL, Navickis RJ, Wilkes MM. Morbidity in hospitalized patients receiving human albumin: a meta-analysis of randomized, controlled trials. *Crit Care Med*. 2004;32(10):2029-2038.
13. Finfer S, Bellomo R, McEvoy M, et al. Effect of baseline serum albumin concentration on outcome of resuscitation with albumin or saline in patients in intensive care units: analysis of data from the Saline versus Albumin Fluid Evaluation (SAFE) Study. *BMJ*. 2006;333:1044.
14. Boldt J, Ducke M, Kumle B, Papsdorf M, Zurmeyer EL. Influence of different volume replacement strategies on inflammation and endothelial activation in the elderly undergoing major abdominal surgery. *Intensive Care Med*. 2004;30(3):416-422.
15. Brunkhorst FM, Engel C, Bloos F, et al. Intensive insulin therapy and pentastarch resuscitation in severe sepsis. *N Engl J Med*. 2008;358(2):125-139.
16. Dart AB, Mutter TC, Ruth CA, Taback SP. Hydroxyethyl starch (HES) versus other fluid therapies: effects on kidney function. *Cochrane Database Syst Rev*. 2010:CD007594.
17. DeBacker D, Créteur J, Dubois MJ, et al. The effects of dobutamine on microcirculatory alterations in patients with septic shock are independent of its systemic effects. *Crit Care Med*. 2006;34:403-408.
18. Vincent JL, Weil MH. Fluid challenge revisited. *Crit Care Med*. 2006;34:1333-1337.
19. Dellinger RP, Levy MM, Carlet JM, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. *Crit Care Med*. 2008;36:296-327.
20. Lorente JA, Landin L, De Pablo R, et al. Effects of blood transfusion on oxygen transport variables in severe sepsis. *Crit Care Med*. 1993;21:1312-1318.
21. Fernandes CJ Jr, Akamine N, De Marco FV, et al. Red blood cell transfusion does not increase oxygen consumption in critically ill septic patients. *Crit Care*. 2001;5(6):362-367.
22. Walsh TS, McArdle F, McLellan SA, et al. Does the storage time of transfused red blood cells influence regional or global indexes of tissue oxygenation in anemic critically ill patients? *Crit Care Med*. 2004;32(2):364-371.
23. Hebert PC, Wells G, Blajchman MA, et al. A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. *N Engl J Med*. 1999;340:409-417.
24. Hebert PC, Yetisir E, Martin C, et al. Is a low transfusion threshold safe in critically ill patients with cardiovascular diseases? *Crit Care Med*. 2001;29(2):227-234.
25. Vincent JL, Baron JF, Reinhart K, et al. Anemia and blood transfusion in critically ill patients. *JAMA*. 2002;288(12):1499-1507.
26. Corwin HL, Gettinger A, Pearl RG, et al. The CRIT Study: anemia and blood transfusion in the critically ill—current clinical practice in the United States. *Crit Care Med*. 2004;32(1):39-52.
27. Weiskopf RB, Viele MK, Feiner J, et al. Human cardiovascular and metabolic response to acute, severe isovolemic anemia. *JAMA*. 1998;279(3):217-221.

28. Howell PJ, Bamber PA. Severe acute anaemia in a Jehovah's Witness. Survival without blood transfusion. *Anaesthesia*. 1987;42(1):44-48.
29. Vincent JL, Sakr Y, Sprung CL, Harboe S, Damas P. Are blood transfusions associated with greater mortality rates? *Anesthesiology*. 2008;108:31-39.
30. Shapiro MJ. To filter blood or universal leukoreduction: what is the answer? *Crit Care*. 2004;(8 Suppl 2):S27-S30.
31. Hebert PC, Fergusson D, Blajchman MA, et al. Clinical outcomes following institution of the Canadian universal leukoreduction program for red blood cell transfusions. *JAMA*. 2003;289:1941-1949.
32. Vamvakas EC. WBC-containing allogeneic blood transfusion and mortality: a meta-analysis of randomized controlled trials. *Transfusion* 2003;43(7):963-973.
33. Fergusson D, Khanna MP, Tinmouth A, Hebert PC. Transfusion of leukoreduced red blood cells may decrease postoperative infections: two meta-analyses of randomized controlled trials. *Can J Anaesth*. 2004;51(5):417-424.
34. Blumberg N, Zhao H, Wang H, et al. The intention-to-treat principle in clinical trials and meta-analyses of leukoreduced blood transfusions in surgical patients. *Transfusion*. 2007;47(4):573-581.
35. Corwin HL, AuBuchon JP. Is leukoreduction of blood components for everyone? *JAMA*. 2003;289(15):1993-1995.
36. Reinelt H, Radermacher P, Kiefer P, et al. Impact of exogenous b-adrenoreceptor stimulation on hepato-splanchnic oxygen kinetics and metabolic activity in septic shock. *Crit Care Med*. 1999;27:325-331.
37. Morelli A, Ertmer C, Rehberg S, et al. Phenylephrine versus norepinephrine for initial hemodynamic support of patients with septic shock: a randomized, controlled trial. *Crit Care*. 2008;12(6):R143.
38. Levy B, Bollaert PE, Charpentier C, et al. Comparison of norepinephrine and dobutamine to epinephrine for hemodynamics, lactate metabolism, and gastric tonometric variables in septic shock. *Intensive Care Med*. 1997;23:282-287.
39. DeBacker D, Créteur J, Silva E, Vincent JL. Effects of dopamine, norepinephrine, and epinephrine on the splanchnic circulation in septic shock: which is best? *Crit Care Med*. 2003;31:1659-1667.
40. Myburgh JA, Higgins A, Jovanovska A, et al. A comparison of epinephrine and norepinephrine in critically ill patients. *Intensive Care Med*. 2008;34(12):2226-2234.
41. Martin C, Papazian L, Perrin G, Saux P, Gouin F. Norepinephrine or dopamine for the treatment of hyperdynamic septic shock? *Chest*. 1993;103:1826-1831.
42. Argalious M, Motta P, Khandwala F, et al. "Renal dose" dopamine is associated with the risk of new-onset atrial fibrillation after cardiac surgery. *Crit Care Med*. 2005;33(6):1327-1332.
43. Bellomo R, Chapman M, Finfer S, Hickling K, Myburgh J. Low-dose dopamine in patients with early renal dysfunction: a placebo-controlled randomised trial. Australian and New Zealand Intensive Care Society (ANZICS) Clinical Trials Group. *Lancet*. 2000;356(9248):2139-2143.
44. Bailey AR, Burchett KR. Effect of low-dose dopamine on serum concentrations of prolactin in critically ill patients. *Br J Anaesth*. 1997;78:97-99.
45. DeBacker D, Biston P, Devriendt J, et al. Comparison of dopamine and norepinephrine in the treatment of shock. *N Engl J Med*. 2010;362(9):779-789.
46. Treschan TA, Peters J. The vasopressin system: physiology and clinical strategies. *Anesthesiology*. 2006;105(3):599-612.
47. Vincent JL. Vasopressin in hypotensive and shock states. *Crit Care Clin*. 2006;22(2):187-197, v.
48. Landry DW, Levin HR, Gallant EM, et al. Vasopressin deficiency contributes to the vasodilation of septic shock. *Circulation* 1997;95(5):1122-1125.
49. Sharshar T, Carlier R, Blanchard A, et al. Depletion of neurohypophyseal content of vasopressin in septic shock. *Crit Care Med*. 2002;30:497-500.
50. Malay MB, Ashton RC Jr, Landry DW, Townsend RN. Low-dose vasopressin in the treatment of vasodilatory septic shock. *J Trauma*. 1999;47(4):699-703.
51. Holmes CL, Walley KR, Chittock DR, Lehman T, Russell JA. The effects of vasopressin on hemodynamics and renal function in severe septic shock: a case series. *Intensive Care Med*. 2001;27(8):1416-1421.
52. Tsuneyoshi I, Yamada H, Kakihana Y, et al. Hemodynamic and metabolic effects of low-dose vasopressin infusions in vasodilatory septic shock. *Crit Care Med*. 2001;29(3):487-493.
53. Patel BM, Chittock DR, Russell JA, Walley KR. Beneficial effects of short-term vasopressin infusion during severe septic shock. *Anesthesiology*. 2002;96(3):576-582.
54. Hall LG, Oyen LJ, Taner CB, et al. Fixed-dose vasopressin compared with titrated dopamine and norepinephrine as initial vasopressor therapy for septic shock. *Pharmacotherapy*. 2004;24(8):1002-1012.
55. Russell JA, Walley KR, Singer J, et al. Vasopressin versus norepinephrine infusion in patients with septic shock. *N Engl J Med*. 2008;358(9):877-887.
56. Holmes CL, Walley KR. Arginine vasopressin in the treatment of vasodilatory septic shock. *Best Pract Res Clin Anaesthesiol*. 2008;22(2):275-286.
57. Russell JA, Walley KR, Gordon AC, et al. Interaction of vasopressin infusion, corticosteroid treatment, and mortality of septic shock. *Crit Care Med*. 2009;37(3):811-818.
58. Argenziano M, Chen JM, Cullinane S, et al. Arginine vasopressin in the management of vasodilatory hypotension after cardiac transplantation. *J Heart Lung Transplant*. 1999;18(8):814-817.
59. Morales DL, Gregg D, Helman DN, et al. Arginine vasopressin in the treatment of 50 patients with postcardiotomy vasodilatory shock. *Ann Thorac Surg*. 2000;69(1):102-106.
60. Morales DL, Garrido MJ, Madigan JD, et al. A double-blind randomized trial: prophylactic vasopressin reduces hypotension after cardiopulmonary bypass. *Ann Thorac Surg*. 2003;75(3):926-930.
61. Stiell IG, Hebert PC, Wells GA, et al. Vasopressin versus epinephrine for in-hospital cardiac arrest: a randomised controlled trial. *Lancet*. 2001;358(9276):105-109.
62. Wenzel V, Krismer AC, Arntz HR, et al. A comparison of vasopressin and epinephrine for out-of-hospital cardiopulmonary resuscitation. *N Engl J Med*. 2004;350(2):105-113.
63. Grmec S, Mally S. Vasopressin improves outcome in out-of-hospital cardiopulmonary resuscitation of ventricular fibrillation and pulseless ventricular tachycardia: a observational cohort study. *Crit Care*. 2006;10(1):R13.
64. Gueugniaud PY, David JS, Chanzy E, et al. Vasopressin and epinephrine vs. epinephrine alone in cardiopulmonary resuscitation. *N Engl J Med*. 2008;359(1):21-30.

65. Albanese J, Leone M, Delmas A, Martin C. Terlipressin or norepinephrine in hyperdynamic septic shock: a prospective, randomized study. *Crit Care Med.* 2005;33(9):1897-1902.
66. Morelli A, Ertmer C, Lange M, et al. Effects of short-term simultaneous infusion of dobutamine and terlipressin in patients with septic shock: the DOBUPRESS study. *Br J Anaesth.* 2008;100(4):494-503.
67. Morelli A, Ertmer C, Rehberg S, et al. Continuous terlipressin versus vasopressin infusion in septic shock (TERLIVAP): a randomized, controlled pilot study. *Crit Care.* 2009;13(4):R130.
68. Boccarda G, Ouattara A, Godet G, et al. Terlipressin versus norepinephrine to correct refractory arterial hypotension after general anesthesia in patients chronically treated with renin-angiotensin system inhibitors. *Anesthesiology.* 2003;98(6):1338-1344.
69. Vincent JL. Understanding cardiac output. *Crit Care.* 2008;12:174.
70. Hayes MA, Timmins AC, Yau EH, et al. Elevation of systemic oxygen delivery in the treatment of critically ill patients. *N Engl J Med.* 1994;330:1717-1722.
71. Renton MC, Snowden CP. Dopexamine and its role in the protection of hepatosplanchnic and renal perfusion in high-risk surgical and critically ill patients. *Br J Anaesth.* 2005;94(4):459-467.
72. Vincent JL, Leon M, Berre J, Melot C, Kahn RJ. Addition of phosphodiesterase inhibitors to adrenergic agents in acutely ill patients. *Int J Cardiol.* 1990;(28 Suppl 1):S7-11.
73. Aranda JM Jr, Schofield RS, Pauly DF, et al. Comparison of dobutamine versus milrinone therapy in hospitalized patients awaiting cardiac transplantation: a prospective, randomized trial. *Am Heart J.* 2003;145(2):324-329.
74. Siostrzonek P, Koreny M, Delle-Karth G, et al. Milrinone therapy in catecholamine-dependent critically ill patients with heart failure. *Acta Anaesthesiol Scand.* 2000;44(4):403-409.
75. Mollhoff T, Loick HM, Van Aken H, et al. Milrinone modulates endotoxemia, systemic inflammation, and subsequent acute phase response after cardiopulmonary bypass (CPB). *Anesthesiology.* 1999;90(1):72-80.
76. Kern H, Schroder T, Kaulfuss M, et al. Enoximone in contrast to dobutamine improves hepatosplanchnic function in fluid-optimized septic shock patients. *Crit Care Med.* 2001;29(8):1519-1525.
77. Toller WG, Stranz C. Levosimendan, a new inotropic and vasodilator agent. *Anesthesiology.* 2006;104(3):556-569.
78. Follath F, Cleland JG, Just H, et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. *Lancet.* 2002;360(9328):196-202.
79. Delaney A, Bradford C, McCaffrey J, Bagshaw SM, Lee R. Levosimendan for the treatment of acute severe heart failure: a meta-analysis of randomised controlled trials. *Int J Cardiol.* 2010;138(3):281-289.
80. Landoni G, Mizzi A, Biondi-Zoccai G, et al. Reducing mortality in cardiac surgery with levosimendan: a meta-analysis of randomized controlled trials. *J Cardiothorac Vasc Anesth.* 2010;24(1):51-57.
81. Guidelines 2000 for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Part 6: advanced cardiovascular life support: section 6: pharmacology II: agents to optimize cardiac output and blood pressure. The American Heart Association in collaboration with the International Liaison Committee on Resuscitation. *Circulation.* 2000;102(8 Suppl):I129-I135.
82. Bennett D. Arterial pressure: A personal view. In: Pinsky MR, Payen D. *Functional Hemodynamic Monitoring.* Heidelberg, Germany: Springer; 2005:89-97.
83. Connors AF Jr, Speroff T, Dawson NV, et al. The effectiveness of right heart catheterization in the initial care of critically ill patients. *JAMA.* 1996;276:889-897.
84. Pinsky MR, Vincent JL. Let us use the PAC correctly and only when we need it. *Crit Care Med.* 2005;33:1119-1122.
85. Friedman G, Berlot G, Kahn RJ, Vincent JL. Combined measurements of blood lactate concentrations and gastric intramucosal pH in patients with severe sepsis. *Crit Care Med.* 1995;23(7):1184-1193.
86. Créteur J. Gastric and sublingual capnometry. *Curr Opin Crit Care.* 2006;12(3):272-277.
87. Russell JA. Gastric tonometry: does it work? [editorial]. *Intensive Care Med.* 1997;23(1):3-6.
88. Gutierrez G, Palizas F, Doglio G, et al. Gastric intramucosal pH as a therapeutic index of tissue oxygenation in critically ill patients. *Lancet.* 1992;339:195-199.
89. Gomersall CD, Joynt GM, Freebairn RC, et al. Resuscitation of critically ill patients based on the results of gastric tonometry: a prospective, randomized, controlled trial. *Crit Care Med.* 2000;28(3):607-614.
90. Silva E, DeBacker D, Créteur J, Vincent JL. Effects of vasoactive drugs on gastric intramucosal pH. *Crit Care Med.* 1998;26:1749-1758.
91. Marik PE, Bankov A. Sublingual capnometry versus traditional markers of tissue oxygenation in critically ill patients. *Crit Care Med.* 2003;31(3):818-822.
92. Créteur J, DeBacker D, Sakr Y, Koch M, Vincent JL. Sublingual capnometry tracks microcirculatory changes in septic patients. *Intensive Care Med.* 2006;32:516-523.
93. DeBacker D, Hollenberg S, Boerma C, et al. How to evaluate the microcirculation: report of a round table conference. *Crit Care.* 2007;11(5):R101.
94. DeBacker D, Créteur J, Preiser JC, Dubois MJ, Vincent JL. Microvascular blood flow is altered in patients with sepsis. *Am J Respir Crit Care Med.* 2002;166(1):98-104.
95. DeBacker D, Créteur J, Dubois MJ, Sakr Y, Vincent JL. Microvascular alterations in patients with acute severe heart failure and cardiogenic shock. *Am Heart J.* 2004;147(1):91-99.
96. Sakr Y, Dubois MJ, DeBacker D, Créteur J, Vincent JL. Persistent microcirculatory alterations are associated with organ failure and death in patients with septic shock. *Crit Care Med.* 2004;32(9):1825-1831.
97. Gomez H, Torres A, Polanco P, et al. Use of non-invasive NIRS during a vascular occlusion test to assess dynamic tissue O(2) saturation response. *Intensive Care Med.* 2008;34(9):1600-1607.
98. Créteur J, Carollo T, Soldati G, et al. The prognostic value of muscle StO2 in septic patients. *Intensive Care Med.* 2007;33(9):1549-1556.
99. Bland RD, Shoemaker WC, Abraham E, Cobo JC. Hemodynamic and oxygen transport patterns in surviving and nonsurviving postoperative patients. *Crit Care Med.* 1985;13:85-90.

100. Bishop M, Shoemaker WC, Appel P, et al. Relationship between supranormal circulatory values, time delays and outcome in severely traumatized patients. *Crit Care Med*. 1993;21:56-63.
101. Boyd O, Grounds M, Bennett ED. A randomized clinical trial of the effect of deliberate perioperative increase of oxygen delivery on mortality in high-risk surgical patients. *JAMA*. 1993;270:2699-2707.
102. Fleming A, Bishop M, Shoemaker WC, et al. Prospective trial of supranormal values as goals of resuscitation in severe trauma. *Arch Surg*. 1992;127:1175-1181.
103. Gattinoni L, Brazzi L, Pelosi P, et al. A trial of goal-oriented hemodynamic therapy in critically ill patients. SvO₂ Collaborative Group. *N Engl J Med*. 1995;333:1025-1032.